Veronique Dartois
Overview
Explore the profile of Veronique Dartois including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
201
Citations
7373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie M, Osiecki P, Rodriguez S, Dartois V, Sarathy J
Curr Protoc
. 2025 Mar;
5(3):e70118.
PMID: 40056090
Tuberculosis (TB) remains one of the leading infectious causes of death worldwide. Persistent bacterial populations in specific microenvironments within the host hamper efficient TB chemotherapy. Caseum in the necrotic core...
2.
Mishra S, Singh P, Hu X, Lopez-Quezada L, Jinich A, Jahn R, et al.
Proc Natl Acad Sci U S A
. 2025 Mar;
122(10):e2425981122.
PMID: 40053362
(Mtb), a leading cause of death from infection, completes its life cycle entirely in humans except for transmission through the air. To begin to understand how Mtb survives aerosolization, we...
3.
Goh J, Patel A, Ngara B, Van Wijk R, Strydom N, Wang Q, et al.
iScience
. 2025 Mar;
28(3):111932.
PMID: 40034847
Multiple potency assays are used to evaluate compounds against , but a consensus on clinically relevant assays is lacking. We aimed to identify an assay signature that predicts preclinical efficacy...
4.
Oluoch P, Koh E, Proulx M, Reames C, Papavinasasundaram K, Murphy K, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(9):e2417525122.
PMID: 39993187
Successful tuberculosis therapy requires treatment with an unwieldy multidrug combination for several months. Thus, there is a growing need to identify novel genetic vulnerabilities that can be leveraged to develop...
5.
Liu Q, Engelhart C, Wallach J, Tiwari D, Ge P, Manna A, et al.
J Med Chem
. 2025 Jan;
68(3):3065-3087.
PMID: 39823202
The antibacterial agent Bio-AMS is metabolized in vivo through hydrolysis of the central acyl-sulfamide linker leading to high clearance and release of a moderately cytotoxic metabolite . Herein, we disclose...
6.
Wang X, Su H, Wallach J, Wagner J, Braunecker B, Gardner M, et al.
Nat Microbiol
. 2025 Jan;
10(2):482-494.
PMID: 39794471
Human challenge experiments could accelerate tuberculosis vaccine development. This requires a safe Mycobacterium tuberculosis (Mtb) strain that can both replicate in the host and be reliably cleared. Here we genetically...
7.
Lyu J, Narum D, Baldwin S, Larsen S, Bai X, Griffith D, et al.
Front Immunol
. 2024 Dec;
15:1427559.
PMID: 39717773
Granulomas, organized aggregates of immune cells which form in response to (), are characteristic but not exclusive of tuberculosis (TB). Despite existing investigations on TB granulomas, the determinants that differentiate...
8.
Negatu D, Aragaw W, Gebresilase T, Paruchuri S, Kaya F, Shin S, et al.
Antimicrob Agents Chemother
. 2024 Nov;
69(1):e0104624.
PMID: 39565116
β-Lactams present several desirable pharmacodynamic features leading to the rapid eradication of many bacterial pathogens. Imipenem (IPM) and cefoxitin (FOX) are injectable β-lactams recommended during the intensive treatment phase of...
9.
Aragaw W, Gebresilase T, Negatu D, Dartois V, Dick T
Antimicrob Agents Chemother
. 2024 Oct;
68(12):e0105124.
PMID: 39470195
Low-level drug resistance in noncanonical pathways can constitute steppingstones toward acquisition of high-level on-target resistance mutations in the clinic. To capture these intermediate steps in (Mab), we performed classic mutant...
10.
Dartois V, Dick T
Clin Microbiol Rev
. 2024 Oct;
37(4):e0008023.
PMID: 39360834
SUMMARYThe opportunistic pathogen (Mab) causes fatal lung infections that bear similarities-and notable differences-with tuberculosis (TB) pulmonary disease. In contrast to TB, no antibiotic is formally approved to treat Mab disease,...